Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open-Label, Multi-Cohort Study to Investigate the Preliminary Antitumor Activity, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With Chemotherapy as First-Line Treatment in Chinese Subjects With Locally Advanced or Metastatic Lung Cancer

Next Previous
X
Search
Trial Profile

A Phase II, Open-Label, Multi-Cohort Study to Investigate the Preliminary Antitumor Activity, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With Chemotherapy as First-Line Treatment in Chinese Subjects With Locally Advanced or Metastatic Lung Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tislelizumab (Primary) ; Carboplatin; Cisplatin; Etoposide; Gemcitabine; Paclitaxel; Pemetrexed
  • Indications Adenocarcinoma; Non-small cell lung cancer; Small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors BeiGene

    • Most Recent Events

    • 25 Nov 2020 Planned End Date changed from 30 Sep 2020 to 1 Dec 2020.
    • 11 Aug 2020 Planned End Date changed from 1 Jul 2020 to 30 Sep 2020.
    • 02 Jun 2020 According to a HTG Molecular Diagnostics media release, results of an analysis assessing gene expression profiles (GEP) associated with response and resistance to tislelizumab using data from three trials (NCT02407990, CTR20160872 and NCT03432598), using HTG EdgeSeq technology was presented as a poster at the 2020 Virtual ASCO conference.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top